TrusTrue Bioscience
- Biotech or pharma, therapeutic R&D
TrusTrue Bioscience is developing a first-in-class humanized antibody that selectively targets toxic, misfolded TDP-43 oligomers in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Alzheimer's disease (AD).
Address
TaipeiTaiwan
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}